Equities

Marksans Pharma Ltd

MARKSANS:NSI

Marksans Pharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)300.50
  • Today's Change11.50 / 3.98%
  • Shares traded6.81m
  • 1 Year change+116.65%
  • Beta1.3135
Data delayed at least 15 minutes, as of Nov 12 2024 10:28 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
OPERATIONS
Net income4,2353,3772,475
Depreciation/depletion743519448
Non-Cash items(188)224(95)
Cash taxes paid, supplemental1,223630729
Cash interest paid, supplemental526142
Changes in working capital(2485)(1745)(1836)
Total cash from operations2,3042,374993
INVESTING
Capital expenditures(2088)(536)(463)
Other investing and cash flow items, total680(2056)(381)
Total cash from investing(1408)(2592)(844)
FINANCING
Financing cash flow items(52)(61)(42)
Total cash dividends paid(227)(102)(106)
Issuance (retirement) of stock, net02,295912
Issuance (retirement) of debt, net(409)(155)32
Total cash from financing(687)1,978795
NET CHANGE IN CASH
Foreign exchange effects00.020
Net change in cash2081,760944
Net cash-begin balance/reserved for future use3,8242,0641,120
Net cash-end balance/reserved for future use4,0333,8242,064
SUPPLEMENTAL INCOME
Depreciation, supplemental743519448
Cash interest paid, supplemental526142
Cash taxes paid, supplemental1,223630729
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.